| Literature DB >> 9809561 |
A F Shields1, J R Grierson, B M Dohmen, H J Machulla, J C Stayanoff, J M Lawhorn-Crews, J E Obradovich, O Muzik, T J Mangner.
Abstract
Positron emission tomography (PET) is now regularly used in the diagnosis and staging of cancer. These uses and its ability to monitor treatment response would be aided by the development of imaging agents that can be used to measure tissue and tumor proliferation. We have developed and tested [F-18]FLT (3'-deoxy-3'-fluorothymidine); it is resistant to degradation, is retained in proliferating tissues by the action of thymidine kinase 1 (TK), and produces high-contrast images of normal marrow and tumors in canine and human subjects.Entities:
Mesh：
Substances：
Year: 1998 PMID： 9809561 DOI： 10.1038/3337
Source DB: PubMed Journal: Nat Med ISSN： 1078-8956 Impact factor: 53.440